Triple Therapy for Atrial Fibrillation after PCI
- 19 October 2017
- journal article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 377 (16), 1580-1582
- https://doi.org/10.1056/nejme1710753
Abstract
The management of atrial fibrillation in patients who have undergone percutaneous coronary intervention (PCI) for the treatment of coronary-artery disease is a common and difficult challenge. In patients with atrial fibrillation, oral anticoagulation is administered to reduce the risk of stroke. In patients who have undergone PCI, dual antiplatelet therapy is administered to prevent major adverse cardiovascular events and stent thrombosis. The use of triple therapy is common in clinical practice; one in four older patients with atrial fibrillation who have had an acute myocardial infarction receives triple therapy.1 Although triple therapy may minimize the risk of stent thrombosis and . . .Keywords
This publication has 8 references indexed in Scilit:
- Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationThe New England Journal of Medicine, 2017
- Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCIThe New England Journal of Medicine, 2016
- Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial FibrillationJournal of the American College of Cardiology, 2015
- Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent ImplantationJournal of the American College of Cardiology, 2015
- Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trialThe Lancet, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial FibrillationJAMA Internal Medicine, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009